COVID-19 prevention drug coming for immunocompromised New Brunswickers – CBC
Evusheld was approved by Health Canada for people aged 12 or older
May 05, 2022
A drug that could prevent immunocompromised people from developing COVID-19 will soon be available in New Brunswick.
Evusheld was approved last month by Health Canada for people aged 12 or older who are immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination, or for whom COVID-19 vaccination is not recommended.
The antibody treatment, developed by AstraZeneca, is administered through two injections before people become infected or have had a known recent exposure to the virus.
“The introduction of this treatment is good news for some specific situations,” Department of Health spokesperson Bruce Macfarlane said in an emailed statement.
“This medication may be part of a treatment plan prescribed by physicians after a clinical assessment to a limited number of individuals.”
